TMA is defined by the triad of microangiopathic anemia, thrombocytopenia, and end-organ damage.33In our cohort we found evidence of microangiopathic anemia (schistocytes/RBC fragments) and intravascular hemolysis (high LDH, indirect bilirubin) in the majority of patients with low ADAMTS13 activity. This evidence concerns the gene ADAMTS13 and Thrombocytopenia.